PRAX
Praxis Precision Medicines I
NASDAQ · Biotechnology
$319.57
+13.95 (+4.56%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 13.09M | 1.51B | 1.36B | 1.44B |
| Net Income | -279,812,693 | -397,237,584 | -445,831,143 | -415,026,051 |
| EPS | — | — | — | — |
| Profit Margin | -2,137.5% | -26.4% | -32.9% | -28.8% |
| Rev Growth | — | +19.5% | +13.8% | +10.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 745.61M | 787.76M | 733.77M |
| Total Equity | — | 3.17B | 3.00B | 2.97B |
| D/E Ratio | — | 0.24 | 0.26 | 0.25 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -305,813,800 | -626,558,933 | -546,408,810 | -551,718,441 |
| Free Cash Flow | — | -309,826,002 | -348,261,984 | -373,057,198 |